Influvac Sub-Unit

Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic, the active ingredient in Influvac Sub-Unit, is a vaccine presented as a subunit formulation for intramuscular or subcutaneous use. It is intended to prevent influenza infection caused by the included influenza A and B virus strains in eligible populations.

GNH USA supplies Influvac Sub-Unit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac Sub-Unit is a subunit influenza vaccine indicated for prevention of influenza caused by influenza A and B viruses.

- Seasonal influenza: provides immunity against circulating influenza A (including A/Vic) and B (including B/Austria/1359417/2021) strains. - High‑risk groups: reduces the risk of influenza‑related complications in the elderly, immunocompromised individuals, and patients with chronic medical conditions. - Pandemic preparedness: contributes to population immunity during influenza seasons when the vaccine strains match circulating viruses.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: transient temperature rise. - Headache: mild headache within 24‑48 hours. - Myalgia: muscle aches. - Fatigue: temporary tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder. - High fever: temperature >39°C persisting beyond 48 hours. - Seizures: especially in children with febrile reactions. - Myocarditis or pericarditis: inflammation of heart muscle or sac. - Severe local reaction: necrosis or abscess at injection site.

Precautions should be observed before administering Influvac Sub-Unit.

- Age restriction: not recommended for infants younger than 6 months. - Allergy: avoid if the patient has a severe allergy to egg proteins or any vaccine component. - Immunocompromised patients: may exhibit reduced immune response; assess benefit‑risk. - Acute illness: defer vaccination in individuals with moderate or severe acute febrile illness. - Pregnancy and lactation: consult a healthcare professional before use. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug and vaccine interactions should be considered.

Major Interactions (Avoid): - Live attenuated vaccines: avoid co‑administration within 4 weeks. - Immunoglobulin therapy: may neutralise vaccine antigens and diminish response. - Antiviral agents started before vaccination (e.g., oseltamivir): can interfere with immunogenicity.

Moderate Interactions (Monitor Closely): - Inactivated vaccines given concurrently: monitor for additive local reactions. - Immunosuppressive drugs (e.g., high‑dose steroids): may reduce antibody production; timing may need adjustment. - Antipyretics taken prophylactically: could blunt the desired immune response; use only if needed.